Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils
- PMID: 17096399
- DOI: 10.1002/da.20251
Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils
Abstract
This article examines evidence for the potential benefit of genetic testing for SSRI response, as well as potential ethical and practical implications of the implementation of this test into standard psychiatric practice. We reviewed three areas of the literature: the burden of treatment-resistant and treatment-intolerant major depressive disorders, the evidence for the value of genetic testing to predict drug response, and the ethical and practical issues of genetic testing in usual care. Treatment resistance and treatment intolerance are common for persons treated with selective serotonin reuptake inhibitors (SSRIs) and are associated with both financial and quality-of-life costs. There is strong evidence from association studies that some polymorphisms are associated with SSRI response. However, no randomized trials have yet tested the efficacy of genetic tests to improve outcome in those with treatment resistance or treatment intolerance to SSRIs. Given the nonspecific nature of the test proposed, several ethical concerns are also involved with administering the genetic tests to patients. A randomized trial comparing response in those treated with standard psychiatric care and in those treated with psychiatric care tailored as a result of genetic test results should be completed before the implementation of these tests can be considered. Additionally, the ethical and practical questions concerning the tests must be addressed now, so that the potential impact of these tests on patient care can be well understood prior to adoption in standard practice.
Similar articles
-
Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).Evid Rep Technol Assess (Full Rep). 2007 Jan;(146):1-77. Evid Rep Technol Assess (Full Rep). 2007. PMID: 17764209 Free PMC article. Review.
-
Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.Biol Psychiatry. 2007 Mar 15;61(6):734-42. doi: 10.1016/j.biopsych.2006.07.017. Epub 2006 Nov 21. Biol Psychiatry. 2007. PMID: 17123473 Clinical Trial.
-
Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors.Int Clin Psychopharmacol. 2007 May;22(3):137-43. doi: 10.1097/YIC.0b013e328014822a. Int Clin Psychopharmacol. 2007. PMID: 17414739
-
Pharmacogenetics in modern psychiatry.Psychiatr Danub. 2007 Sep;19(3):231-3. Psychiatr Danub. 2007. PMID: 17914325
-
Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence.Pharmacotherapy. 2017 Sep;37(9):1089-1104. doi: 10.1002/phar.1978. Epub 2017 Aug 11. Pharmacotherapy. 2017. PMID: 28654193 Review.
Cited by
-
Clinical implications of genetic variation in the serotonin transporter promoter region: a review.Prim Care Companion J Clin Psychiatry. 2009;11(3):93-102. doi: 10.4088/pcc.08r00656. Prim Care Companion J Clin Psychiatry. 2009. PMID: 19617941 Free PMC article.
-
Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment.Psychopharmacology (Berl). 2013 Jun;227(3):509-19. doi: 10.1007/s00213-013-2995-y. Epub 2013 Feb 14. Psychopharmacology (Berl). 2013. PMID: 23407780
-
Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):395-409. doi: 10.1016/j.pnpbp.2010.10.019. Epub 2010 Oct 31. Prog Neuropsychopharmacol Biol Psychiatry. 2011. PMID: 21044654 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical